President, Commercial Ops Recupero Anthony J sold $160,732 worth of shares (9,531 units at $16.86), decreasing direct ownership by 3% to 287,866 units (SEC Form 4)

$SIBN
Medical/Dental Instruments
Health Care
Get the next $SIBN alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RECUPERO ANTHONY J

(Last) (First) (Middle)
C/O SI-BONE, INC.
471 EL CAMINO REAL, SUITE 101

(Street)
SANTA CLARA CA 95050

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SI-BONE, Inc. [ SIBN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President, Commercial Ops
3. Date of Earliest Transaction (Month/Day/Year)
02/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/18/2025 S(1) 940 D $17.3682(2) 296,457 D
Common Stock 02/18/2025 S(1) 3,343 D $16.9709(3) 293,114 D
Common Stock 02/18/2025 S(1) 2,126 D $16.7494(4) 290,988 D
Common Stock 02/18/2025 S(1) 1,504 D $16.7003(5) 289,484 D
Common Stock 02/18/2025 S(1) 1,304 D $16.7186(5) 288,180 D
Common Stock 02/18/2025 S(1) 314 D $16.3854(6) 287,866(7) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
2. This transaction was executed in multiple trades at prices ranging from $17.29 USD to $17.40 USD; the price reported above reflects the weighted average sale price.
3. This transaction was executed in multiple trades at prices ranging from $16.29 USD to $17.28 USD; the price reported above reflects the weighted average sale price.
4. This transaction was executed in multiple trades at prices ranging from $16.35 USD to $16.95 USD; the price reported above reflects the weighted average sale price.
5. This transaction was executed in multiple trades at prices ranging from $16.37 USD to $16.945 USD; the price reported above reflects the weighted average sale price.
6. This transaction was executed in multiple trades at prices ranging from $16.26 USD to $16.51 USD; the price reported above reflects the weighted average sale price.
7. Includes 177,850 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock.
Remarks:
/s/ Michael A. Pisetsky, Attorney-in-Fact for Anthony J. Recupero 02/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $SIBN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SIBN

DatePrice TargetRatingAnalyst
8/6/2024$27.00 → $19.00Buy
Needham
3/28/2024$25.00Overweight
Piper Sandler
10/12/2022$20.00Buy
Jefferies
4/7/2022$34.00Overweight
Cantor Fitzgerald
3/1/2022$30.00 → $28.00Overweight
Morgan Stanley
1/18/2022$43.00 → $36.00Buy
B of A Securities
12/21/2021$35.00 → $30.00Buy
Truist Securities
11/9/2021$42.00 → $36.00Market Outperform
JMP Securities
More analyst ratings

$SIBN
Press Releases

Fastest customizable press release news feed in the world

See more
  • SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance

    SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $49.0 million, representing growth of ~26%  U.S. revenue of $46.9 million, representing growth of ~28%Gross margin of ~79%Net loss of $4.5 million, representing an improvement of ~59%Positive adjusted EBITDA of $1.9 million, representing an improvement of ~139%Ended the quarter with $150.0 million in cash and equivalents, representing $0

    $SIBN
    Medical/Dental Instruments
    Health Care
  • Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    $BRKR
    $PGNY
    $SIBN
    $SWAV
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care
  • SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025

    SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/xyxunb4k. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archi

    $SIBN
    Medical/Dental Instruments
    Health Care

$SIBN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SIBN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SIBN
SEC Filings

See more

$SIBN
Leadership Updates

Live Leadership Updates

See more
  • Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    $BRKR
    $PGNY
    $SIBN
    $SWAV
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care
  • Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors

    Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. "We are pleased to welcome these two transformational business leaders as new independent directors on the Board," said David Brabazon, Chairman of the Mainstay Board of Directors. "Their deep experience will be invaluable to Mainstay as we grow our business and pursue our mission to serve patients with intractable chronic low back pain." "As our business evolves and we continue to focus on commercial growth, broadening the industry expertise on our Board will help

    $SIBN
    Medical/Dental Instruments
    Health Care
  • SI-BONE Appoints Anshul Maheshwari as Chief Financial Officer and Announces the Addition of Helen Loh and Laura Francis to the Board of Directors

    SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the compa

    $SIBN
    Medical/Dental Instruments
    Health Care

$SIBN
Financials

Live finance-specific insights

See more
  • SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance

    SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $49.0 million, representing growth of ~26%  U.S. revenue of $46.9 million, representing growth of ~28%Gross margin of ~79%Net loss of $4.5 million, representing an improvement of ~59%Positive adjusted EBITDA of $1.9 million, representing an improvement of ~139%Ended the quarter with $150.0 million in cash and equivalents, representing $0

    $SIBN
    Medical/Dental Instruments
    Health Care
  • SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025

    SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/xyxunb4k. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archi

    $SIBN
    Medical/Dental Instruments
    Health Care
  • SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

    SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Piper Sandler Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, December 4, 2024, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://event.webcasts.com/starthere.jsp?ei=1696941&tp_key=589204a98b. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast

    $SIBN
    Medical/Dental Instruments
    Health Care

$SIBN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more